All Type of News
In the top 100 pharmaceutical products, Green Cross, Dong-A and Chong Kun Dang listed 14, 10 and 7 products each
It is known that Green Cross ranked the highest number of products in the top 100 pharmaceutical products manufactured by pharmaceutical companies last year.
In the ‘2014 Actual Output Chart for Pharmaceutical Produc...
Listed pharmaceutical companies made KRW 54 million profits by investing KRW 1 billion equity
It is analyzed that listed pharmaceutical companies have made KRW 54 million profits per KRW 1 billion equity invested last year.
Considering they made KRW 81 million profits per KRW 1 billion equity invested in 2013...
As the Baxter’s ‘Baxalta’ is founded, it appointed Nah-kyung Kim as the new president of its Korean branchA global biopharmaceutical companies, Baxalta, announced on the 16th that the company appointed Nah-kyung Kim, the business unit director of the company, as the new president of...
|
Forxiga will be accepted to be used for the dual therapy with insulin while Suglat is going to be newly registeredThe insurance benefit standard of diabetes drugs has been expanded. Followed by DPP-4 inhibitors, the dual therapy of a SGLT-2 inhibitor, ‘Forxiga(dapagliflozin),’ is also expec...
|
Bayer develops the follow-up NOAC of Xarelto, strengthening its pipelineBayer has put much effort on the development of another new oral anticoagulant(NOAC).
According to the industry concerned on the 17th, the new oral anticoagulant is a factor XI...
|
Celebrex has faced significant prescription reduction while its generics are not popular in the market, either
Celebrex, the Pfizer’s COX-2 type anti-inflammatory drug, has encountered significant decreases in prescriptions due to entry of its generics. Celebrex, whose patent was expired on the 11th last June, has faced generi...
The new drugs domestically approved in the first quarter
New drugs approved in this first quarter appear to be outstanding.
According to the present condition of pharmaceutical approvals from the Ministry of Health and Welfare, starting with the Novartis Korea’s Zykadia(ge...
The National Health Insurance Corporation re-attempted the adoption of IC Card, a possible way to prevent the 2nd MERS crisis
“If electronic health insurance cards(IC Card) are adopted, it would be unnecessary to renew health insurance on paper every year and the theft problem of health insurance cards and the repetition treatment problem wo...
Chong Kun Dang and Pfizer will co-promote 2 glaucoma treatment productsChong Kun Dang is going to target the leading product market of a prostaglandin-type glaucoma treatment with Pfizer.
Chong Kun Dang(President Young-joo Kim) announced on the 16...
|
.jpg)
Over the pressure of the pharmaceutical industry to delay the Drug Price Reduction, the Ministry of Health and Welfare stated “as it is scheduled”
Over the argument of the pharmaceutical industry to defer the Drug Price Reduction followed by the Real Transaction Price Investigation, the Ministry of Health and Welfare has expressed negative opinions.
On the 14th...
